Details

Autor(en) / Beteiligte

• Regules, Jason A
• Beigel, John H
• Paolino, Kristopher M
• Voell, Jocelyn
• Castellano, Amy R
• Hu, Zonghui
• Muñoz, Paula
• Moon, James E
• Ruck, Richard C
• Bennett, Jason W
• Twomey, Patrick S
• Gutiérrez, Ramiro L
• Remich, Shon A
• Hack, Holly R
• Wisniewski, Meagan L
• Josleyn, Matthew D
• Kwilas, Steven A
• Van Deusen, Nicole
• Mbaya, Olivier Tshiani
• Zhou, Yan
• Stanley, Daphne A
• Jing, Wang
• Smith, Kirsten S
• Shi, Meng
• Ledgerwood, Julie E
• Graham, Barney S
• Sullivan, Nancy J
• Jagodzinski, Linda L
• Peel, Sheila A
• Alimonti, Judie B
• Hooper, Jay W
• Silvera, Peter M
• Martin, Brian K
• Monath, Thomas P
• Ramsey, W. Jay
• Link, Charles J
• Lane, H. Clifford
• Michael, Nelson L
• Davey, Richard T
• Thomas, Stephen J

Titel

A Recombinant Vesicular Stomatitis Virus Ebola Vaccine

Ist Teil von

• The New England journal of medicine, 2017-01, Vol.376 (4), p.330-341

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2017

Quelle

MEDLINE

Beschreibungen/Notizen

• This final report updates preliminary data on an attenuated, replication-competent, recombinant vesicular stomatitis virus–based vaccine candidate designed to prevent Ebola virus disease. The results supported the safety and immunogenicity of up to two doses of the vaccine. The worst Ebola virus disease (EVD) outbreak in recorded history has resulted in more than 28,000 cases and 11,000 reported deaths. 1 Although the primary strategy to stop the transmission of Ebola remains the identification and isolation of contacts and the use of appropriate personal protective equipment, the development of a safe and efficacious vaccine would provide an important public health tool. Numerous Ebola virus vaccine candidates are in preclinical development, and some have proceeded to human trials. 2 – 5 An Ebola virus vaccine candidate based on an attenuated, replication-competent, recombinant vesicular stomatitis virus (rVSV) has shown promise in preclinical studies. The . . .